Oncology
Refine Search
Biotechnology
Japanese drugmaker Takeda has launched Fruzaqla (fruquintinib) in its home country. 22 November 2024
Biotechnology
Chinese biopharma CStone Pharmaceuticals has announced a strategic commercial collaboration with Pharmalink Store, a prominent pharmaceutical company based in the United Arab Emirates (UAE). 22 November 2024
Biotechnology
Privately-held US biotech Alloy Therapeutics has announced a strategic collaboration and license agreement with Takeda Pharmaceutical. 21 November 2024
Pharmaceutical
Japanese drugmaker Eisai has announced that the amyotrophic lateral sclerosis (ALS) treatment Rozebalamin for Injection (mecobalamin) has been launched in Japan as a treatment for slowing progression of functional impairment in amyotrophic lateral sclerosis. 21 November 2024
Biotechnology
The US Food and Drug Administration (FDA) has granted accelerated approval of Ziihera (zanidatamab-hrii) 50mg/mL for injection for intravenous use, say the drug’s developer, Jazz Pharmaceuticals. 21 November 2024
Biotechnology
San Diego-based Kura Oncology and Japan’s Kyowa Kirin have entered into a global strategic collaboration to develop and commercialize ziftomenib. 21 November 2024
Pharmaceutical
Shanghai-based Leading Tac Pharmaceutical has announced the successful completion of a series A financing round, raising over 100 million yuan ($14 million). 21 November 2024
Biotechnology
US biotech major Amgen has announced that Dr Howard Chang will join the company as senior vice president of research, effective December 16, 2024. 21 November 2024
Biotechnology
Bioplatform company builder Flagship Pioneering has announced its companies Ampersand Biomedicines and Montai Therapeutics have entered into agreements to identify targeted molecules that could potentially be further developed as treatments for obesity and lung cancer. 20 November 2024
Pharmaceutical
Ascentage Pharma will see its investigational BCL-2 selective inhibitor, lisaftoclax, assessed under China’s Priority Review scheme. 20 November 2024
Biosimilars
Sweden-based Xbrane Biopharma and Intas Pharmaceuticals have announced an exclusive global licensing and co-development agreement for the former company’s Opdivo (nivolumab) biosimilar candidate. 20 November 2024
Biotechnology
A pair of industry veterans have teamed up to create Jupiter Bioventures, a San Francisco-based biotech venture foundry promised to build bold, science-driven therapeutics companies. 20 November 2024
Biotechnology
The UK’s health technology assessor the Institute for Health and Clinical Excellence (NICE) says that talks with the makers of Enhertu have ended without agreement, meaning guidance that does not recommend Enhertu for advanced breast cancer will remain unchanged. 20 November 2024
Biotechnology
German biotech CatalYm has followed up a groundbreaking 2023 with an impressive 2024. 19 November 2024
Biotechnology
US pharma giant Merck & Co today announced positive top-line results from the pivotal Phase III MK-3475A-D77 trial for its mega blockbuster drug Keytruda (pembrolizumab) in subcutaneous form. 19 November 2024
Biotechnology
Privately-held US biotech Georgiamune has announced the appointment of Mark Avagliano as chief business officer (CBO). 19 November 2024
Biotechnology
Germany’s Lindis Biotech, a specialist in multi-specific antibody platforms, has announced an exclusive licensing agreement with Pharmanovia, for the commercialization of Korjuny (catumaxomab). 19 November 2024
Biotechnology
Californian oncology-focused biotech Avenzo Therapeutics has announced a pair of important updates. 19 November 2024
Pharmaceutical
Swiss cancer giant Novartis has entered into an exclusive worldwide licensing and collaboration deal with Ratio Therapeutics, aiming to develop a next-generation radiotherapeutic. 19 November 2024
Biotechnology
The US Food and Drug Administration has approved Dupixent (dupilumab) for the treatment of children with eosinophilic esophagitis. 26 January 2024
Biotechnology
Shares of Dutch biotech LAVA Therapeutics shot up 43% to $2.23 by close of trading on Thursday, after it revealed a clinical trial collaboration and supply agreement with US pharma giant Merck & Co. 26 January 2024
Biotechnology
Products from biotech major Gilead Sciences appear twice on a US Food and Drug Administration (FDA) list of six cell therapies that are to carry black box warnings about the risk of T-cell malignancies. 25 January 2024
Biotechnology
Korean immuno-oncology company CanariaBio has taken a stock market battering following the failure of its Phase III trial of oregovomab, an antibody targeting CA125, for ovarian cancer patients. 25 January 2024
Biotechnology
San Diego, USA-based precision cancer medicines developer Kura Oncology saw its shares rocket more than 46% to $19.62 yesterday it announced a $150 million oversubscribed private placement. 25 January 2024
Biotechnology
Sino-American RNAi therapeutics company Sirnaomics today announced he publication of a research article with NAR Cancer. 24 January 2024
Biotechnology
Unnatural Products (UNP), a biotech company pairing AI with chemistry to enable the next generation of molecularly targeted therapeutics, has announced a collaboration with US pharma giant Merck & Co. 24 January 2024
Pharmaceutical
Accent Therapeutics, a US biopharma seeking to develop a new class of small molecule precision cancer therapies, has announced the completion of a $75 million Series C financing. 23 January 2024
Pharmaceutical
US healthcare giant Johnson & Johnson announced its fourth-quarter and annual financial results for 2023 on Tuesday. 23 January 2024
Pharmaceutical
Shares of US radiopharmaceuticals-focussed Lantheus Holdings (Nasdaq: LNTH) were down 5.4% at $51.88 by late morning today, as it announced the appointment of Brian Markison, current board chairman and industry veteran, to the position of chief executive (CEO), effective as of March 1, 2024. 23 January 2024
Biotechnology
This week in The Pharma Letter Podcast, we are speaking with the chief executive of British drug development company Ellipses Pharma. 23 January 2024
Biotechnology
Small biotechs continue to show more interest in a public listing in 2024, with ArriVent Biopharma the latest to opt for an initial public offering (IPO) in the USA. 23 January 2024
Biotechnology
The US Food and Drug Administration (FDA) is adding black box warnings on six cell therapies about the risk of T-cell malignancies. 23 January 2024
Biotechnology
US biotech major Gilead Sciences is staring down the barrel of a 10% decline in its market value on Monday due to a setback with a key oncology asset. 22 January 2024
Biotechnology
Mirae Asset has launched a biotech-focused affiliate, with $50 million to invest in the life sciences. 22 January 2024
Biotechnology
Bristol Myers Squibb has announced impressive results from the Phase III CheckMate -8HW trial evaluating Opdivo (nivolumab) plus Yervoy (ipilimumab). 22 January 2024
Pharmaceutical
Last Friday, the US Food and Drug Administration (FDA) approved Balversa (erdafitinib), from healthcare giant Johnson & Johnson's (NYSE: JNJ) subsidiary Janssen. 22 January 2024
Pharmaceutical
The convergence of cutting-edge technologies and breakthroughs in the scientific understanding of cancer have enabled unprecedented opportunities for precision oncology (PO), according to a posting on the European Federation of Pharmaceutical Industries and Associations (EFPIA). 22 January 2024
Pharmaceutical
Medullary thyroid carcinoma (MTC) is a rare neuroendocrine condition that develops in the parafollicular C cells of the thyroid gland.1 It makes up 3%-5% of all thyroid cancers, with a 10-year mortality rate of about 50%.2 20 January 2024
Biotechnology
The UK's National Institute for Health and Care Excellence (NICE) has published final draft guidance recommending Talzenna (talazoparib) for HER2- negative, locally advanced or metastatic breast cancer with germline BRCA1 or BRCA2 mutations in adults. 19 January 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze